Ocular Surface Disease

The OTC eye drops contain low-dose brimonidine tartrate 0.025%.

BRS Analytical Service, LLC, an independent contract testing laboratory, initiated the recall because of possible concerns about product quality and safety linked to the manufacturing process. An FDA audit revealed serious manufacturing violations of Current Good Manufacturing Practice.

Identifying allergens or irritants can be challenging, but a few strategies can help patients find relief.

An emerging treatment approach for a commonly underdiagnosed ocular surface disease.

Inflammation is both a cause and consequence of dry eye disease.

Nordic Pharma plans to announce commercialization details in the near future for the dry eye disease treatment.

An overview of prescription medications available for DED.

Cationic emulsion drops are characterized by their ability to retain cyclosporine A on the ocular surface.

The dynamic muscle stimulation device is a noninvasive option for patients experiencing lower lid laxity and impaired blinking.

Annual reports of the occurrence of adverse effects associated with the use of cosmetics increased from 2006 to 2018, then decreased from 2018 to 2021.

Preservatives may disrupt the ocular surface, contributing to poor adherence.

This year was brimming with advancements in eye care.

According to Mile Brujic, OD, FAAO, low-level light therapy (LLLT) and intense pulsed light have demonstrated tremendous benefits for his patients.

Aurion Biotech announced that Phase 1/2 CLARA trial of AURN001 for corneal edema demonstrated significant dose-dependent efficacy, especially in the high-dose group, with favorable safety and tolerability profiles.

The University of Colorado study found that patient visits for irritation and allergies more than double during high particulate matter levels, emphasizing the need for proactive clinical strategies.

Inside the role of blepharitis in ocular surface disease and effective management strategies.

All 6 biomarkers in the study demonstrated improvement with the treatment of lifitegrast, according to Thimons.

The retrospective study investigated and analyzed the severity and frequency of ocular pain and factors affecting it among DED patients living in high altitudes above 2500 meters during the COVID-19 pandemic.

Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.

Tracy Doll, OD, FAAO, details portions of the Tear Film and Ocular Surface Society Lifestyle Report, which discussed certain risk factors that we may have for development of ocular surface dryness or dry eye.

What we know and what we do not know…yet.

Lisa Hornick, OD, MBA, FAAO, outlines key findings from the report on the impacts of healthy cosmetic habits and reducing digital eye strain.